Advertisement
Screener

Alkermes plc. (ALKS) Overview

Alkermes plc. (ALKS) Overview

  • 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual 0.00; Beat / miss (m).
  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual -0.40; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual 0.49; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual 0.52; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$25.84$30.37$35.70$41.97$49.33$57.982025-11-062026-11-06$20.40$25.14$30.98$38.18$47.05$57.982021-11-082026-11-06$12.41$17.57$24.88$35.22$49.88$70.622016-11-072026-11-06$5.79$9.90$16.90$28.86$49.28$84.152006-11-062026-11-06$0.95$2.43$6.19$15.80$40.34$102.961991-07-162026-11-06

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$45.92
Previous close
$40.80
Change
$5.12
Change (%)
12.55%
Close date
2026-11-06
Previous close date
2026-09-29
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

ALKS
+45.82%
S&P 500
(m)

1 year

ALKS
+40.50%
S&P 500
(m)

3 years

ALKS
+45.66%
S&P 500
(m)

5 years

ALKS
+32.00%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

30 Jun 2026 ○ Estimate (m) ● Actual 0.00

-0.48-0.190.110.400.7031 Mar 2025: estimate (m); actual 0.1331 Mar 2025(m)30 Jun 2025: estimate (m); actual 0.5230 Jun 2025(m)30 Sept 2025: estimate (m); actual 0.4930 Sept 2025(m)31 Mar 2026: estimate (m); actual -0.4031 Mar 2026(m)30 Jun 2026: estimate (m); actual 0.0030 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202630 Jun 2026(m)0.00(m)(m)
1 Jan 202631 Mar 2026(m)-0.40(m)(m)
1 Jul 202530 Sept 2025(m)0.49(m)(m)
1 Apr 202530 Jun 2025(m)0.52(m)(m)
1 Jan 202531 Mar 2025(m)0.13(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual 1.43

-1.05-0.200.651.502.3531 Dec 2021: estimate (m); actual -0.2931 Dec 2021(m)31 Dec 2022: estimate (m); actual -0.9731 Dec 2022(m)31 Dec 2023: estimate (m); actual 2.1031 Dec 2023(m)31 Dec 2024: estimate (m); actual 2.1731 Dec 2024(m)31 Dec 2025: estimate (m); actual 1.4331 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)1.43(m)(m)
1 Jan 202431 Dec 2024(m)2.17(m)(m)
1 Jan 202331 Dec 2023(m)2.10(m)(m)
1 Jan 202231 Dec 2022(m)-0.97(m)(m)
1 Jan 202131 Dec 2021(m)-0.29(m)(m)

Revenue vs. Earnings

USD

30 Jun 2026 ■ Revenue 496.01M ■ Earnings 0.50M — Profit margin 0.10%

-133.98M-17.9%98.52M-4.6%331.01M8.7%563.51M22.0%30 Sept 2025: revenue 394.19M; earnings 82.76M; profit margin 21.00%30 Sept 202531 Dec 2025: revenue 384.55M*; earnings 49.38M*; profit margin 12.84%*; Revenue: Annual amount − nine-month amount; Earnings: Annual amount − nine-month amount; period 2025-10-01 to 2025-12-31; USD.31 Dec 202531 Mar 2026: revenue 392.91M; earnings -66.48M; profit margin -16.92%31 Mar 202630 Jun 2026: revenue 496.01M; earnings 0.50M; profit margin 0.10%30 Jun 2026

31 Dec 2025 ■ Revenue 1.48B ■ Earnings 0.24B — Profit margin 16.38%

-0.38B-15.2%0.38B-2.0%1.13B11.3%1.88B24.6%31 Dec 2022: revenue 1.11B; earnings -0.16B; profit margin -14.24%31 Dec 202231 Dec 2023: revenue 1.66B; earnings 0.36B; profit margin 21.39%31 Dec 202331 Dec 2024: revenue 1.56B; earnings 0.37B; profit margin 23.57%31 Dec 202431 Dec 2025: revenue 1.48B; earnings 0.24B; profit margin 16.38%31 Dec 2025

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$45.92(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$45.92High(m)Average(m)Low(m)2025-11-062026-11-06

Recent news

View more →

(m)

YouTube videos mentioning ALKS

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-11; financial period ending (m).

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
(m)
Profit margin
(m)
Return on assets · 12 month
(m)
Stock compensation expense · all employees · 12 months
(m)
Named executive and board stock awards · latest fiscal year
(m)
Index membership
(m)
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
2.18M
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
-5.75%*
Total return · month
-13.94%*
Total return · quarter
-22.33%*
Total return · half year
38.82%*
Total return · year to date
45.82%*
Total return · 1 year
40.50%*
Total return · 3 years
45.66%*
Total return · 5 years
32.00%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
(m)
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
(m)
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

Alkermes plc. Overview

View more →

(m)

(m)

SEC CIK
1520262
Industry (SIC)
2834 Pharmaceutical Preparations
Country of operation
(m)
Business address
CONNAUGHT HOUSE, 1 BURLINGTON ROAD, DUBLIN 4, 00000
Fiscal year end
1231
Phone
00-353-1-772-8000

Similar stocks

Stock NameCountryMarket CapPE Ratio
RHYTHM PHARMACEUTICALS, INC. (RYTM)United States$6.771B-37.20
IONIS PHARMACEUTICALS INC (IONS)United States$7.277B-23.25
Liquidia Corp (LQDA)United States$6.347B51.23
Amneal Pharmaceuticals, Inc. (AMRX)$6.326B25.62
Spyre Therapeutics, Inc. (SYRE)United States$7.685B-43.69
Structure Therapeutics Inc. (GPCR)United States$7.710B-53.41
Praxis Precision Medicines, Inc. (PRAX)United States$7.884B-27.60
Mirum Pharmaceuticals, Inc. (MIRM)United States$5.798B-8.81
Travere Therapeutics, Inc. (TVTX)United States$5.712B-123.10
Oruka Therapeutics, Inc. (ORKA)United States$5.663B-43.76